Low mortality oxidative stress murine chronic wound model. Issue 1 (7th September 2020)

• Record Type: Journal Article
• Authors: Panayi, Adriana C; Endo, Yori; Karvar, Mehran; Sensharma, Prerana; Haug, Valentin; Fu, Siqi; Mi, Bobin; An, Yang; Orgill, Dennis P
• Is Part Of: BMJ open diabetes research and care. Volume 8:Issue 1(2020)
• Publication Date: 2020-09-07
• Subjects: chronic wound(s) -- mouse model(s) -- regeneration -- wound healing; Diabetes -- Periodicals; 616.462005
• DOI: 10.1136/bmjdrc-2020-001221
• Languages: English
• ISSNs: 2052-4897

Abstract

Abstract : Introduction: Investigators have struggled to produce a reliable chronic wound model. Recent progress with antioxidant enzyme inhibitors shows promise, but mortality rates are high. We modified the dosage and administration of an antioxidant enzyme inhibitor regimen to reduce mortality while inducing a chronic wound environment. Research design and methods: To chemically induce a chronic wound environment, we applied modified doses of catalase (3-amino-1, 2, 4-triazole; intraperitoneal 0.5 g/kg) and glutathione peroxidase (mercaptosuccinic acid; topical 300 mg/kg) inhibitors to the dorsal wounds of 11-week-old db/db mice. A cohort of these mice was treated with a collagen-glycosaminoglycan scaffold. Both groups were compared with Diabetic control mice. Results: This study successfully induced a chronic wound in 11-week-old db/db mice, with no animal deaths. The antioxidant enzyme treated groups showed delayed wound contraction and significantly higher levels of inflammatory tissue, collagen deposition, cellular proliferation and leukocyte infiltration than the Diabetic control group. Angiogenesis was significantly higher in the antioxidant enzyme treated groups, but the vessels were immature and friable. Scaffold engraftment was poor but appeared to promote blood vessel maturation. Conclusions: Overall, the two in vivo groups treated with the antioxidant enzyme inhibitors appeared to be arrested in the inflammatory stage of wound healing, while the Diabetic control group progressed to the maturation phase and ultimately remodeling. This model may be instrumental for the development of new wound therapeutics.